ARTICLE | Clinical News
NitroMed reports Phase II data
June 26, 2000 7:00 AM UTC
NitroMed (Bedford, Mass.) said data from a 24-patient study showed that its NMI-870, a nitric oxide (NO)-enhanced compound of the alpha2 blocker yohimbine, increased vaginal blood flow in post-menopau...